|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-10-17
|
|
pubmed:abstractText |
Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:BairdJ KevinJK,
pubmed-author:BangsMichael JMJ,
pubmed-author:BarcusMazie JMJ,
pubmed-author:BasriHasanH,
pubmed-author:ChulayJeffrey DJD,
pubmed-author:FryauffDavid JDJ,
pubmed-author:GramzinskiRobertR,
pubmed-author:HoffmanStephen LSL,
pubmed-author:LacyMark DMD,
pubmed-author:LingJudithJ,
pubmed-author:MaguireJason DJD,
pubmed-author:MillerGerri BGB,
pubmed-author:SismadiPriyantoP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e92-5
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12384852-Adolescent,
pubmed-meshheading:12384852-Adult,
pubmed-meshheading:12384852-Aged,
pubmed-meshheading:12384852-Animals,
pubmed-meshheading:12384852-Antimalarials,
pubmed-meshheading:12384852-Atovaquone,
pubmed-meshheading:12384852-Double-Blind Method,
pubmed-meshheading:12384852-Drug Resistance,
pubmed-meshheading:12384852-Drug Therapy, Combination,
pubmed-meshheading:12384852-Female,
pubmed-meshheading:12384852-Humans,
pubmed-meshheading:12384852-Indonesia,
pubmed-meshheading:12384852-Malaria, Falciparum,
pubmed-meshheading:12384852-Malaria, Vivax,
pubmed-meshheading:12384852-Male,
pubmed-meshheading:12384852-Middle Aged,
pubmed-meshheading:12384852-Naphthoquinones,
pubmed-meshheading:12384852-Plasmodium falciparum,
pubmed-meshheading:12384852-Plasmodium vivax,
pubmed-meshheading:12384852-Proguanil,
pubmed-meshheading:12384852-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.
|
|
pubmed:affiliation |
Parasitic Diseases Program, US Naval Medical Research Unit 2, Jakarta, Indonesia.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
